NCT06973187 2026-03-18
A Study to Evaluate the Safety and Efficacy of BGB-16673 Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
BeOne Medicines
Phase 3 Recruiting
Clinical Trials
54 trialsNCT07277231 2026-03-18
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3 Recruiting
NCT04269902 2026-03-17
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
National Cancer Institute (NCI)
Phase 3 Recruiting
NCT03486873 2026-03-16
MK-3475-587
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT04628026 2026-03-16
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
University of Ulm
Phase 3 Recruiting
NCT06136559 2026-03-16
BELLWAVE-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT05254743 2026-03-12
BRUIN-CLL-314
Eli Lilly and Company
Phase 3 Recruiting
NCT04939090 2026-03-04
Olanzapine Versus Megestrol Acetate for the Treatment of Loss of Appetite Among Advanced Cancer Patients
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT06943872 2026-03-04
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
BeOne Medicines
Phase 3 Recruiting
NCT07132684 2026-03-02
Comparison of VA and D/IA Induction Regimens in Elderly Fit Acute Myeloid Leukemia Patients
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT06578247 2026-02-27
QuANTUM-WILD
Daiichi Sankyo
Phase 3 Recruiting
NCT04293562 2026-02-24
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Children's Oncology Group
Phase 3 Recruiting
NCT05711667 2026-02-24
A Study of the Drug Letermovir as Prevention of Cytomegalovirus Infection After Stem Cell Transplant in Pediatric Patients
Children's Oncology Group
Phase 3 Recruiting
NCT04094311 2026-02-17
Study of Out of Specification for Tisagenlecleucel
Novartis
Phase 3 Recruiting
NCT07211958 2026-02-04
REVEAL-ND NPM1
Syndax Pharmaceuticals
Phase 3 Recruiting
NCT05429632 2026-01-30
MO-TRANS
Priothera SAS
Phase 3 Recruiting
NCT07186192 2026-01-28
Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy
City of Hope Medical Center
Phase 3 Recruiting
NCT06852222 2026-01-16
cAMeLot-2
Janssen Research & Development, LLC
Phase 3 Recruiting
NCT04448184 2026-01-08
PATH
Ottawa Hospital Research Institute
Phase 3 Recruiting
NCT05327894 2026-01-08
Interfant-21
Princess Maxima Center for Pediatric Oncology
Phase 3 Recruiting
NCT06970743 2026-01-07
CaDAnCe-303
BeOne Medicines
Phase 3 Recruiting
NCT05645107 2025-12-16
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma
Grifols Therapeutics LLC
Phase 3 Recruiting
NCT06389292 2025-11-25
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT06647862 2025-11-25
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3 Recruiting
NCT07232134 2025-11-20
AML-DS-2025
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting
NCT07139873 2025-11-18
A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6)
Dizal Pharmaceuticals
Phase 3 Recruiting
NCT06428019 2025-11-05
A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
AbbVie
Phase 3 Recruiting
NCT04829539 2025-10-20
Comparing Brief Behavioral Therapy (BBT-CI) and Healthy Eating Education Learning (HEAL) for Cancer-Related Sleep Problems While Receiving Cancer Treatment
University of Rochester
Phase 3 Recruiting
NCT07203352 2025-10-02
Efficacy of Targeted Drugs Combined With Chemotherapy in the Treatment of T-ALL
Nanfang Hospital, Southern Medical University
Phase 3 Recruiting
NCT07152041 2025-09-03
CAMS-Ph+ B-ALL
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Recruiting
NCT04307576 2025-08-28
A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia
Karolinska University Hospital
Phase 3 Recruiting
NCT07075016 2025-08-19
EVOLVE 1
Stichting Hemato-Oncologie voor Volwassenen Nederland
Phase 3 Recruiting
NCT06387069 2025-08-14
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Hutchmed
Phase 3 Recruiting
NCT06990321 2025-08-08
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
The First Hospital of Jilin University
Phase 3 Recruiting
NCT06401356 2025-06-22
An Extension Study for Patients Previously Enrolled in Studies With Pelabresib
Novartis
Phase 3 Recruiting
NCT06423911 2025-06-03
POLARIS-2
Ascentage Pharma Group Inc.
Phase 3 Recruiting
NCT05907057 2025-04-11
An Open-label Phase 3b Study of Ivosidenib in Combination With Azacitidine in Adult Patients Newly Diagnosed With IDH1m Acute Myeloid Leukemia (AML) Ineligible for Intensive Induction Chemotherapy.
Servier
Phase 3 Recruiting
NCT05586074 2025-04-09
HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML
Sunshine Lake Pharma Co., Ltd.
Phase 3 Recruiting
NCT03643276 2025-04-06
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017
University Hospital Schleswig-Holstein
Phase 3 Recruiting
NCT04547049 2025-03-25
A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies
First Affiliated Hospital of Zhejiang University
Phase 3 Recruiting
NCT04043494 2025-03-21
LBL 2018
University Hospital Muenster
Phase 3 Recruiting
NCT04314219 2025-03-13
PTCy-PMAT
King Faisal Specialist Hospital & Research Center
Phase 3 Recruiting
NCT05991908 2025-02-18
Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT06829472 2025-02-17
Conditioning Regimen of Melphalan-busulfan and Fludarabine: a Randomized Study of Different Dose of Melphalan
Shanghai Jiao Tong University School of Medicine
Phase 3 Recruiting
NCT06810791 2025-02-06
HVA vs IA/DA or VA in the Treatment of ND HR-AML
Nanfang Hospital, Southern Medical University
Phase 3 Recruiting
NCT04168502 2024-11-08
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Gruppo Italiano Malattie EMatologiche dell'Adulto
Phase 3 Recruiting
NCT03459534 2024-10-28
A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure or Intolerance to Previous TKIs
Il-Yang Pharm. Co., Ltd.
Phase 3 Recruiting
NCT05726110 2024-10-22
Selinexor in Combination With HAD or CAG Rregimens in Relapsed or Refractory Acute Myeloid Leukemia
Shanxi Bethune Hospital
Phase 3 Recruiting
NCT05753384 2024-07-29
Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System
Poitiers University Hospital
Phase 3 Recruiting
NCT05029531 2024-06-28
Combined Immuno-chemotherapy for Patients With B-linear Acute Lymphoblastic Leukemia Diagnosed From 0 to 365 Days of Life (ALL-Baby-2021)
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Phase 3 Recruiting